Summary of Beta Bionics FY Conference Call Company Overview - **Company**: Beta Bionics (NasdaqGM: BBNX) - **Product**: iLet insulin delivery system, a differentiated insulin pump with automation features [19][20] Key Industry Insights - **Market Positioning**: Beta Bionics believes it is well-positioned to capture new patients in the insulin pump market due to its unique automation capabilities, which reduce the need for patient and healthcare provider engagement [20][21] - **Competitive Landscape**: The company identifies shortcomings in competitors' devices, particularly in algorithmic automation and patient engagement [23][24] - **Patient Demographics**: The company is attracting two main patient groups: early adopters of technology and those who struggle with traditional insulin pumps [32][33] Product Differentiation - **Automation**: The iLet pump uses a learning algorithm that adapts to the patient's needs, allowing for a more personalized insulin delivery experience [20][21] - **Ease of Use**: The product is designed to require minimal engagement from both patients and healthcare providers, making it easier to prescribe and manage [21][60] - **Market Opportunity**: The insulin pump market is still under-penetrated, with significant growth potential as more patients transition from injections to pumps [28][33] Sales and Market Strategy - **Sales Territories**: Beta Bionics currently operates in approximately 63 territories and plans to add at least 20 new territories in 2026, aiming for a total of 120-180 territories to effectively compete [66][72] - **Sales Force Expansion**: The company emphasizes a calculated approach to expanding its sales force, focusing on hiring high-performing salespeople [78][79] - **Primary Care Engagement**: There is a growing recognition of the importance of primary care physicians in managing diabetes, with many Type 1 patients being treated in primary care settings [54][61] Pipeline and Future Products - **Mint Patch Pump**: Expected to be commercialized by the end of 2027, the Mint patch pump will feature a reusable component and aims to provide a user-friendly experience [92][93] - **Bi-Hormonal System**: This innovative product aims to improve patient outcomes by incorporating glucagon to prevent hypoglycemia, with ongoing clinical trials planned [100][103] Competitive Dynamics - **Industry Trends**: The company acknowledges the need for behavior change within the healthcare community regarding insulin pump usage, which may take time [48][49] - **Validation of Strategy**: Competitors adopting similar reimbursement models (e.g., pay-as-you-go) are seen as validation of Beta Bionics' pioneering approach [104][106] Conclusion - Beta Bionics is positioned to leverage its innovative technology and unique business model to capture market share in the insulin delivery space, with a focus on automation and ease of use for both patients and healthcare providers. The upcoming Mint product and bi-hormonal system represent significant growth opportunities for the company.

Achieved $100.3 million in 2025 net sales, representing 54% year-over-year growth driven by a doubling of the installed base to 35,000 users. Attributed sales force productivity to the iLet's fully automated algorithm and digital ecosystem, which allowed a smaller team of 63 territories to compete effectively against larger incumbents. Successfully executed a pharmacy channel strategy, establishing formulary agreements with all major U.S. PBMs to lower patient out-of-pocket costs and drive high-margin ...

Financial Data and Key Metrics Changes - The company reported net sales of $100.3 million for the full year 2025, representing a 54% year-over-year growth [11] - Gross margin for the full year was 55.4%, slightly expanding year-over-year [11] - In Q4, net sales reached $32.1 million, reflecting a 57% growth year-over-year [12] - Q4 gross margin was 59%, an increase of 179 basis points year-over-year [14] Business Line Data and Key Metrics Changes - The company added approximately 20,000 new users in 2025, more than doubling its installed base to over 35,000 users [8] - New patient starts through the pharmacy channel grew to the high 20s percentage for the full year 2025, compared to a high single-digit percentage in the prior year [11] - In Q4, 5,592 new patient starts were recorded, a 37% increase year-over-year [12] Market Data and Key Metrics Changes - Approximately 69% of new patient starts in Q4 came from individuals previously using multiple daily injections, indicating market expansion [17] - The company established formulary agreements with all major pharmacy benefit managers in the U.S. [9] Company Strategy and Development Direction - The company aims to revolutionize diabetes care by improving outcomes and reducing the burden for users [7] - The focus is on expanding the pharmacy channel strategy and enhancing the product pipeline, including the development of the Mint patch pump and the bihormonal system [10][39] - The company plans to add at least 20 new sales territories in 2026 to enhance market coverage [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 2026 revenue guidance of $130 million to $135 million, despite potential headwinds from pharmacy channel dynamics [19] - The company anticipates a decline in Q1 2026 revenue compared to Q4 2025 due to seasonal factors [22][70] - Management remains optimistic about the long-term potential of the bihormonal system and its ability to transform diabetes management [42] Other Important Information - The company received a Warning Letter from the FDA regarding quality system observations, which management is actively addressing [30][38] - As of December 31, 2025, the company had approximately $265 million in cash and investments, indicating strong capitalization for future initiatives [18] Q&A Session Summary Question: Can you discuss the level of conservatism in the 2026 guidance? - Management refrained from labeling the guidance as conservative but expressed confidence in meeting the communicated targets [47] Question: What is the outlook for gross margin in 2026? - The guidance for gross margin was slightly lower than expected due to potential short-term headwinds from pharmacy conversions [49][51] Question: How did the pump market perform in Q4? - Management did not have specific insights on market share due to competitors not yet reporting their earnings [55] Question: Can you elaborate on the sales territory expansion? - The company plans significant expansion in the first half of 2026, with at least 20 new territories being added [60] Question: What are the concerns regarding hypoglycemia? - Management indicated that rates of hypoglycemia are consistent with clinical trials and are significantly lower than ADA guidelines [86]

Financial Data and Key Metrics Changes - The company reported net sales of $100.3 million for the full year 2025, representing a 54% year-over-year growth [11] - Gross margin for the full year was 55.4%, slightly expanding year-over-year [11] - In Q4, net sales reached $32.1 million, reflecting a 57% growth year-over-year [12] - Q4 gross margin was 59%, an increase of 179 basis points year-over-year [14] Business Line Data and Key Metrics Changes - The company added approximately 20,000 new users in 2025, more than doubling the installed base to over 35,000 users [8] - New patient starts through the pharmacy channel grew to the high 20s percentage for the full year 2025, compared to a high single-digit percentage in the prior year [11] - In Q4, 5,592 new patient starts were recorded, a 37% increase year-over-year [12] Market Data and Key Metrics Changes - Approximately 69% of new patient starts in Q4 came from individuals previously using multiple daily injections, indicating market expansion [17] - The company established formulary agreements with all major pharmacy benefit managers in the U.S. [9] Company Strategy and Development Direction - The company aims to revolutionize diabetes care by improving outcomes and reducing the burden for users [7] - The focus is on expanding the pharmacy channel strategy and enhancing the product pipeline, including the development of the Mint patch pump and the Bihormonal System [10][39] - The company plans to add at least 20 new sales territories in 2026 to enhance market coverage [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to resolve FDA concerns and improve quality systems following a warning letter [30][38] - The company anticipates continued growth in the pharmacy channel, which is expected to drive revenue and gross margin improvements [20][28] - Management highlighted the importance of maintaining cost discipline while expanding operations [19] Other Important Information - The company has approximately $265 million in cash and investments, indicating strong capitalization to fund key initiatives [18] - The guidance for 2026 includes expected revenue of $130 million to $135 million and gross margin between 55.5% and 57.5% [19] Q&A Session Summary Question: Can you discuss the level of conservatism in the 2026 guidance? - Management indicated confidence in hitting the guidance but acknowledged that outperforming in the pharmacy channel could create short-term revenue headwinds [48] Question: What is the outlook for gross margin in 2026? - Management explained that the gross margin guidance reflects potential short-term impacts from increased pharmacy conversions [49][50] Question: How did the pump market perform in Q4? - Management stated they do not have insights on market share performance yet as competitors have not reported their earnings [54] Question: Can you elaborate on the sales territory expansion? - Management confirmed that a significant portion of the territory expansion will occur in the first half of 2026 [58] Question: Why is the company expanding by only 20 territories? - Management emphasized a deliberate approach to expansion, balancing growth with operational capabilities and future product launches [81]

Financial Data and Key Metrics Changes - For the full year 2025, Beta Bionics reported net sales of $100.3 million, representing a 54% year-over-year growth. The gross margin was 55.4%, which expanded slightly year-over-year [10][11] - In Q4 2025, the company generated $32.1 million in net sales, reflecting a 57% growth year-over-year, with a gross margin of 59%, an increase of 179 basis points year-over-year [11][12] Business Line Data and Key Metrics Changes - The company added approximately 20,000 new users in 2025, more than doubling its installed base to over 35,000 users [6][10] - In Q4, 5,592 new patient starts were recorded, a 37% increase year-over-year, with a growing percentage of new patient starts reimbursed through the pharmacy channel [11][12] Market Data and Key Metrics Changes - The percentage of new patient starts through the pharmacy channel grew to the high 20s% for the full year 2025, compared to a high single-digit percentage in the previous year [10][12] - In Q4, approximately 69% of new patient starts came from individuals who previously used multiple daily injections, indicating an expansion of the market for insulin pumps [16] Company Strategy and Development Direction - Beta Bionics aims to revolutionize diabetes care by improving access and outcomes for people with diabetes through innovative products like the iLet and the upcoming Mint patch pump [5][9] - The company has established formulary agreements with major pharmacy benefit managers, enhancing user access to the iLet and its consumables at lower out-of-pocket costs [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to continue expanding the pump market and capturing market share, with revenue guidance for 2026 set at $130 million to $135 million [18][19] - The company acknowledged challenges related to seasonality in the insulin pump market, particularly the expected decline in Q1 2026 revenue compared to Q4 2025 [21][23] Other Important Information - The company received a Warning Letter from the FDA regarding quality system observations, which management is actively addressing through remediation efforts [29][30] - Beta Bionics is progressing with its R&D initiatives, including the development of the Mint patch pump and the bihormonal system, with significant milestones achieved in clinical trials [40][41] Q&A Session Summary Question: Can you discuss the level of conservatism in the 2026 guidance? - Management refrained from labeling the guidance as conservative but expressed confidence in meeting the communicated revenue targets, considering potential headwinds from pharmacy channel performance [46][47] Question: What is the outlook for the U.S. pump market in Q4? - Management did not provide specific insights on market share due to competitors not yet reporting their earnings [53][55] Question: How will the expansion of sales territories impact market coverage? - The company plans to add at least 20 new sales territories in 2026, with a significant portion of this expansion occurring in the first half of the year [56][60] Question: What are the expectations for Q1 2026 revenue? - Management indicated that Q1 2026 is expected to see a larger decline in revenue compared to the previous year, influenced by unique product launches in Q4 2024 [63][68] Question: How does the company address concerns regarding hypoglycemia? - Management stated that the rates of hypoglycemia with the iLet are consistent with clinical trials and significantly lower than ADA guidelines, emphasizing the safety of their product [85][86]

Other factors that may cause the Company's actual results to differ from current expectations are discussed in the Company's filings with the Securities and Exchange Commission (the "SEC"), including the section titled "Risk Factors" in the Company's Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on October 28, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation is given. Except as required by law, ...

Summary of Beta Bionics FY Conference Call (December 02, 2025) Company Overview - **Company**: Beta Bionics (NasdaqGM: BBNX) - **Product**: iLet, a diabetes management system utilizing a patch pump Key Industry Insights - **Market Adoption**: The company is experiencing strong adoption of its product, with sales productivity being notable despite a smaller sales force compared to competitors like Tandem [1][2] - **Patient Demographics**: Approximately 70% of patients are transitioning from Multiple Daily Injections (MDI), with over 25% being Type 2 diabetes patients, which is atypical for pump users [7][9] - **Clinical Outcomes**: The iLet system has shown significant clinical outcomes, with a median A1c reduction from 9.7 to 7.5 in patients who are not actively bolusing [13][14] Product Performance - **Ease of Use**: The simplicity and effectiveness of the iLet system resonate well with both patients and clinicians, leading to good outcomes without extensive effort [2][6] - **Market Access Challenges**: A significant portion of clinics remain closed to sales representatives, limiting market access and adoption [3][4] - **Competitive Conversions**: About 30% of new patients are coming from competitive conversions, indicating a strong interest in the iLet algorithm and its effectiveness [15][16] Financial Performance - **Revenue Growth**: The company anticipates adding approximately 19,000 patients in the upcoming year, with a projected revenue increase of around $31 million for 2026 [29][37] - **Pharmacy Channel Success**: There has been notable growth in the pharmacy channel, with nearly doubling the number of patients compared to the previous quarter [21][22] - **Pricing Dynamics**: The company does not foresee significant pricing erosion despite competition, as their pricing model differs from competitors like Tandem [26][27] Product Development and Future Outlook - **Patch Pump Development**: The company is focused on the development of a new patch pump, with expectations for FDA approval in the coming year and a full launch by 2027 [39][46] - **Innovation and Efficiency**: The company emphasizes quick decision-making and a focused approach to product development, which has allowed for rapid progress in bringing new products to market [40][44] - **Market Disruption**: Beta Bionics aims to disrupt the diabetes management market not only through product innovation but also by improving profitability timelines compared to traditional industry standards [54][55] Additional Considerations - **Patient Experience**: The use of a steel cannula is positioned as beneficial for patients, particularly for those with scar tissue, countering common misconceptions about discomfort [48][49] - **Algorithm Efficiency**: The iLet algorithm is highlighted as a key differentiator, providing effective management without the need for frequent manual adjustments [18][53] This summary encapsulates the critical insights and developments discussed during the Beta Bionics FY conference call, highlighting the company's strategic positioning and future growth potential in the diabetes management market.

Core Insights - Beta Bionics, Inc. (BBNX) reported revenue of $27.25 million for the quarter ended September 2025, showing no change from the same period last year, with an EPS of -$0.33 compared to $0 in the previous year [1] - The revenue exceeded the Zacks Consensus Estimate of $23.92 million by +13.96%, while the EPS surprised positively by +26.67% against the consensus estimate of -$0.45 [1] Revenue Breakdown - Total DME channel revenue was $21.02 million, surpassing the average estimate of $16.22 million from two analysts [4] - Total PBP channel revenue reached $6.24 million, exceeding the average estimate of $5.65 million from two analysts [4] - PBP channel revenue from single-use products was $6.09 million, compared to the average estimate of $5.94 million [4] - DME channel revenue from single-use products was $6.84 million, exceeding the average estimate of $5.48 million [4] - PBP channel revenue from iLet was $0.15 million, below the average estimate of $0.5 million [4] - DME channel revenue from iLet was $14.18 million, surpassing the average estimate of $10.74 million [4] Stock Performance - Beta Bionics, Inc. shares have returned +19.6% over the past month, significantly outperforming the Zacks S&P 500 composite, which changed by +3.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - The company reported net sales of $27.3 million for Q3 2025, representing a 63% year-over-year growth [7] - Gross margin improved to 55.5%, up 212 basis points from 53.4% in Q3 2024 and up 167 basis points sequentially from 53.8% in Q2 2025 [10] - Total operating expenses increased to $32.2 million, a 62% rise compared to $19.9 million in Q3 2024 [14] - Cash, cash equivalents, and investments stood at approximately $274 million as of September 30, 2025, indicating sufficient capitalization for key initiatives [15] Business Line Data and Key Metrics Changes - The growth in revenue was driven by 5,334 new patient starts, which grew 68% year-over-year [8] - Approximately 70% of new patient starts in Q3 came from individuals previously using multiple daily injections, indicating market expansion [13] - The percentage of new patient starts reimbursed through the pharmacy channel was in the low 30s, significantly higher than the high single-digit percentage from the previous year [8][9] Market Data and Key Metrics Changes - Over 80% of insured lives in the U.S. are covered under formulary agreements with major pharmacy benefit managers (PBMs) [8] - The company expects 27%-29% of new patient starts to be reimbursed through the pharmacy channel for the full year 2025, an increase from prior guidance [15][16] Company Strategy and Development Direction - The company aims to disrupt the diabetes management industry with innovative products like the iLet and the Mint patch pump [19][20] - The focus remains on driving adoption of the iLet as a pharmacy benefit at the health plan level [9] - The company is committed to expanding its pipeline with new features and products to enhance user experience and clinical outcomes [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business direction, citing strong demand for the iLet and positive real-world outcomes [10][11] - The company raised its full-year 2025 revenue guidance to over $96.5 million, up from previous estimates [15] - Management acknowledged potential variability in pharmacy mix due to seasonal dynamics and ongoing adoption efforts [16] Other Important Information - The company received a special 510(k) clearance for updates to the iLet, improving usability and reducing alert fatigue [23] - A Form 483 was issued by the FDA regarding the company's complaint handling system, but management is confident in their remediation efforts [24][25] Q&A Session Summary Question: What is driving the momentum in revenue growth? - Management indicated that the success is due to the unique positioning of the iLet as a new category of device, with increasing adoption over time [33] Question: Can you elaborate on the patient demographics for new starts? - Approximately one-third of the remaining 30% of new patients are converting from competitive pump systems, with consistent demand patterns observed [39] Question: What is the impact of the FDA Form 483 on operations? - Management stated that they are actively addressing the issues raised and have implemented new systems to ensure compliance [49][50] Question: How does the company view future pharmacy channel growth? - Management expressed uncertainty in predicting specific thresholds for pharmacy channel penetration but aims to maximize the number [92]

Financial Data and Key Metrics Changes - The company reported net sales of $27.3 million for Q3 2025, representing a 63% year-over-year growth [7] - Gross margin improved to 55.5%, up 212 basis points from 53.4% in Q3 2024 and up 167 basis points sequentially from 53.8% in Q2 2025 [10] - Total operating expenses increased to $32.2 million, a 62% rise compared to $19.9 million in Q3 2024 [14] - The company has approximately $274 million in cash and investments as of September 30, 2025, indicating strong capitalization for future initiatives [15] Business Line Data and Key Metrics Changes - The growth in revenue was driven by 5,334 new patient starts in Q3, which grew 68% year-over-year [8] - A low 30s percentage of new patient starts were reimbursed through the pharmacy channel, significantly higher than the high single-digit percentage in Q3 of the previous year [8][9] - Approximately 70% of new patient starts came from individuals previously using multiple daily injections, indicating market expansion [13] Market Data and Key Metrics Changes - The company has over 80% of insured lives in the U.S. covered under formulary agreements with pharmacy benefit managers [8] - The market for insulin pumps remains underpenetrated, with significant opportunities for growth from both type 1 and type 2 diabetes patients [40] Company Strategy and Development Direction - The company aims to disrupt the industry with innovative products like the iLet and the Mint patch pump, focusing on user experience and clinical outcomes [19][20] - The updated full-year 2025 guidance projects total revenue to exceed $96.5 million, up from previous guidance of $88 to $93 million [15][17] - The company is committed to driving adoption of the iLet under pharmacy benefits at the health plan level [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business direction, citing strong demand for the iLet and ongoing innovation in the pipeline [10][11] - The company anticipates continued growth in pharmacy mix and gross margin due to increased scale and high-margin recurring revenue from the pharmacy installed base [17][66] - Management acknowledged potential variability in new patient starts and pharmacy mix due to seasonal dynamics [16] Other Important Information - The company received a special 510(k) clearance for updates to the iLet, improving usability and reducing alert fatigue [23] - The FDA issued a Form 483 related to the company's customer complaint handling system, which management is addressing through remediation efforts [24][25] Q&A Session Summary Question: What is driving the momentum in revenue growth? - Management indicated that the success is due to the unique positioning of the iLet as a new category of device, with increasing adoption over time [33] Question: Can you elaborate on the patient demographics for new starts? - Approximately one-third of the remaining 30% of new patients are converting from competitive pump systems, with consistent demand patterns observed [39] Question: What is the impact of the FDA Form 483? - Management stated that they are actively addressing the issues raised and have implemented new systems to ensure compliance [49][50] Question: How does the government shutdown affect Mint's launch? - Management confirmed that the government shutdown does not currently impact their expectations for the Mint launch timeline [35] Question: What are the growth drivers for next year? - Continued understanding of the iLet and expansion of pharmacy adoption are expected to drive growth into next year [64][66]